Alteon preclinical data

ALTN presented a new class of orally active agents that lower glucose and free fatty acids in animal models of Type II diabetes. The lead compound, ALT-4000, lowered glucose in diabetic mice, as reported at the meeting of the American Diabetes Association in San Francisco. Mice with the ob/ob gene mutation receiving daily, intraperitoneal injections of 50 mg/kg of the agent had lower blood glucose levels after eating, and the effect was more pronounced after 66 days than at 36 days of treatment. Blood glucose also was reduced by the treatment in GMI Zucker diabetic rats.

Decreases in free fatty acids and glycerol preceded improved blood glucose, suggesting that the mechanism of action involves fat metabolism. ...